Want to see IN:AARTIPHARM full AI Analyst Report?
AARTIPHARM Stock Chart & Stats
₹842.40
₹9.55(1.45%)
At close: 4:00 PM EST
₹842.40
₹9.55(1.45%)
Day’s Range― - ―
52-Week Range₹583.85 - ₹971.50
Previous CloseN/A
Volume141.60K
Average Volume (3M)18.67K
Market Cap
₹64.02B
Enterprise Value₹66.21B
Total Cash (Recent Filing)₹555.56M
Total Debt (Recent Filing)₹6.59B
Price to Earnings (P/E)33.9
Beta0.89
Next Earnings
Aug 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.67%
Share Statistics
EPS (TTM)26.45
Shares Outstanding90,657,750
10 Day Avg. Volume12,195
30 Day Avg. Volume18,670
Financial Highlights & Ratios
PEG Ratio-0.92
Price to Book (P/B)2.71
Price to Sales (P/S)3.16
P/FCF Ratio-30.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
B2B API ManufacturingAarti Pharmalabs' core business is large-scale API and intermediate manufacturing, a durable B2B model supplying formulators and chemical customers. Specialized process chemistry and scale create sticky demand, steady volume-based revenues, and strategic customer ties that persist beyond short-term cycles.
Historically Solid MarginsConsistent operating and net margins across FY2023–FY2025 indicate underlying cost and process advantages. Margin resilience offers a buffer to raw-material swings, supports reinvestment in capacity or R&D, and signals operational efficiency that supports earnings durability over multiple quarters.
Positive Operating Cash FlowPositive operating cash flow shows the business can convert earnings into cash, supporting working-capital needs and routine capex. This cash-generation capacity is a durable strength that can fund operations and investments, even if free cash flow is episodically impacted by higher capex or working-capital swings.
Bears Say
Rising LeverageA material step-up in borrowings in FY2026 reduces financial flexibility and raises interest and refinancing risk. Higher leverage limits the company's ability to absorb demand shocks or fund growth internally, increasing reliance on external financing and making long-term strategic moves more costly.
Weakening Revenue And EarningsA decline in revenue and a sharp drop in net income in FY2026 signal structural pressure on demand, pricing, or mix. Sustained top-line and earnings weakness can erode utilization, weaken operating leverage, and limit the company's ability to invest in higher-value molecules or maintain margins over ensuing quarters.
Negative Free Cash FlowMeaningful negative free cash flow across FY2025–FY2026 indicates investment or working-capital strains exceeding operating cash generation. Persistently negative FCF raises dependence on debt or equity raises, complicates debt servicing given higher leverage, and constrains long-term reinvestment capacity.
Aarti Pharmalabs Limited News
AARTIPHARM FAQ
What was Aarti Pharmalabs Limited’s price range in the past 12 months?
Aarti Pharmalabs Limited lowest stock price was ₹583.85 and its highest was ₹971.50 in the past 12 months.
What is Aarti Pharmalabs Limited’s market cap?
Aarti Pharmalabs Limited’s market cap is ₹64.02B.
When is Aarti Pharmalabs Limited’s upcoming earnings report date?
Aarti Pharmalabs Limited’s upcoming earnings report date is Aug 03, 2026 which is in 27 days.
How were Aarti Pharmalabs Limited’s earnings last quarter?
Aarti Pharmalabs Limited released its earnings results on May 25, 2026. The company reported ₹6.74 earnings per share for the quarter, beating the consensus estimate of N/A by ₹6.74.
Is Aarti Pharmalabs Limited overvalued?
According to Wall Street analysts Aarti Pharmalabs Limited’s price is currently Overvalued.
Does Aarti Pharmalabs Limited pay dividends?
Aarti Pharmalabs Limited pays a Semiannually dividend of ₹1.5 which represents an annual dividend yield of 0.67%. See more information on Aarti Pharmalabs Limited dividends here
What is Aarti Pharmalabs Limited’s EPS estimate?
Aarti Pharmalabs Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aarti Pharmalabs Limited have?
Aarti Pharmalabs Limited has 90,657,750 shares outstanding.
What happened to Aarti Pharmalabs Limited’s price movement after its last earnings report?
Aarti Pharmalabs Limited reported an EPS of ₹6.74 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 2.666%.
Which hedge fund is a major shareholder of Aarti Pharmalabs Limited?
Currently, no hedge funds are holding shares in IN:AARTIPHARM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aarti Pharmalabs Limited
Aarti Pharmalabs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients, pharmaceutical intermediates, and xanthine derivatives in India and internationally. The company offers active pharmaceutical ingredients for various therapeutic areas, such as cardiovascular, anti-asthmatic, anti-cancer, anti-coagulant, anti-diabetic, arthritis, central nervous system agent, skincare, overactive bladder, calcimimetic, decongestant, anti-thalassaemic, analgesic, and ophthalmologic medications. It also provides contract development and manufacturing services for drug substance projects. In addition, the company offers intermediates; xanthine derivatives, including caffeine, theophylline anhydrous, aminophylline, etophylline, and theophylline; and acid and allied products, including sulphuric acid, sulphur trioxide, oil, dimethyl sulphate, diethyl sulphate, and sodium vinyl sulfonate. The company was formerly known as Aarti Organics Limited. Aarti Pharmalabs Limited was incorporated in 2019 and is headquartered in Mumbai, India.
Technical Analysis
Bliss Gvs Pharma Limited
―
FDC Ltd.
―
Gufic Biosciences Limited
―
IOL Chemicals & Pharmaceuticals Ltd.
―
Orchid Pharma Limited
―